Immunomic Therapeutics adds John H. Sampson to scientific advisory board
Tuesday, August 1, 2017
Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to welcome a new oncology advisor, Duke University’s John H. Sampson, M.D., Ph.D., to the Immunomic scientific advisory board as the company pursues application of the investigational LAMP-Vax platform technology in oncology.
Dr. Sampson will advise on scientific and technical matters relating to brain tumors and the application of LAMP-Vax in oncology, including the new research combining LAMP technology and a cytomegalovirus (CMV) immunotherapy platform, recently announced in a licensing agreement between Immunomic and Annias Immunotherapeutics. The agreement aims to support and accelerate development of a potential new generation of cancer immunotherapy. Currently, the Phase II trial, called ATTAC-II (NCT02465268), is recruiting participants with newly-diagnosed glioblastoma (GBM).
“Immunomic Therapeutics has focused on nucleic acid-based vaccines and is working to enhance the immunogenicity of vaccine formulations through its LAMP technology. These efforts are aimed at advancing cancer vaccine development for pediatric and adult patients with brain cancer,” said Dr. Sampson. “Current studies are underway to determine whether LAMP technology has the potential to alter oncology treatment and I am pleased to be working with Immunomic to further GBM research.”
Dr. Sampson is at the forefront of neurosurgery and is highly regarded for his innovative research in drug delivery to the brain and immunotherapy for brain tumors. Sampson serves as Duke University’s Chair for the Department of Neurosurgery. He is also the Robert H. and Gloria Wilkins Distinguished Professor of Surgery. Sampson earned his Ph.D. from Duke University Medical Center in neuro-oncology and completed his residency and fellowship at Duke University Medical Center.
“We are thrilled to welcome Dr. Sampson to our scientific advisory board,” stated Teri Heiland, Ph.D., Immunomic’s Senior Vice President of Research and Development. “His expertise will provide a tremendous resource as we continue to explore application of LAMP technology in oncology.”